Table 2.
Selected current or upcoming JAK2/STAT3 and NF-κB pathway inhibitor clinical trials.
| Clinical Trial ID | Drug | Pathway | Molecular target | Tumor | Phase | Timeline |
|---|---|---|---|---|---|---|
| NCT00910728 | AZD1480 | JAK2/STAT3 | JAK2 | Myeloproliferative disorders | I/II | Recruiting |
| NCT00639002 | INCB018424 | JAK2/STAT3 | JAK2 | Multiple myeloma | II | Ongoing |
| NCT00079482 | CEP-701 | JAK2/STAT3 | JAK2 | AML | II | Ongoing |
| NCT00696176 | STAT 3 DECOY | JAK2/STAT3 | STAT3 | Head and neck cancer | 0 | Recruiting |
| NCT00955812 | OPB-31121 | JAK2/STAT3 | STAT3 | Solid tumors | I | Recruiting |
| NCT00522574 | XL019 | JAK2/STAT3 | JAK2 | Myeloproliferative disorders | I | Ongoing |
| NCT00077467 | Bortezomib | NF-κB | Proteosome | AML, ALL | I | Completed |
| NCT00572637 | CEP-18770 | NF-κB | Proteosome | Solid tumors, NHL | I | Recruiting |
| NCT00667082 | NPI-0052 | NF-κB | Proteosome | Lung, pancreatic, melanoma, lymphoma | I | Recruiting |
| NCT00199212 | PS-341 | NF-κB | Proteosome | Metastatic breast cancer | I | Recruiting |
| NCT00396864 | NPI-0052 | NF-κB | Proteosome | Solid tumors, lymphomas | I | Recruiting |
| NCT00376948 | Genistein | NF-κB | IκBα??? | Pancreatic cancer | II | Ongoing |
ALL: Acute lymphocytic leukemia; AML: Acute myeloid leukemia; NHL: Non-Hodgkin lymphoma.